WallaceLovellAkerleyIIIMD

Clinical Trials

• S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Jan 01

  Completed

  Phase 2

• Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer Start of enrollment: 2007 Aug 01

  Completed

  Phase 2

• A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2004 Jun 01

  Completed

  Phase 2

• Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer Start of enrollment: 2013 Dec 02

  Completed

  Phase 1

• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08

  Completed

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• Tumor Treating Fields for Locally Advanced NSCLC Start of enrollment: 2024 Apr 04

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Join now to see all